In the same year, Johnson et al. [212] conducted the first pediatric phase I study (NCT02502708) on the use of indoximod, an oral inhibitor of the IDO (indoleamine 2,3-dioxygenase) pathway, in pediatric patients with recurrent brain tumors or newly diagnosed DIPG. The gene discussed is IDO2; the disease is brain neoplasm.